The authors applied non-negative matrix factorization to refine cellular subtypes of SCLC and found that there were two inflamed subsets with different clinical outcomes dependent on the ratio of T-effector to tumor-associated macrophage infiltration; inflammatory tumors with high CD8 T cells and low macrophages (~14% of their population) showed enhanced benefit. The gene discussed is CD8A; the disease is neoplasm.